TIDMIMM
Immupharma PLC
05 November 2012
FOR IMMEDIATE RELEASE 5 NOVEMER 2012
RNS REACH
ImmuPharma to Present Lupuzor(TM) Phase IIb Abstract / Clinical
Paper at
2012 Annual ACR Meeting, Washington, D.C.
Presentation Date: 14 November 2012
ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is pleased to
confirm that it will be presenting at the 2012 Annual American
College of Rheumatology ("ACR") Meeting which is being held between
11 - 14 of November. ImmuPharma will be presenting on Wednesday 14
November 2012. The ACR Annual Scientific Meeting is the premier
scientific meeting devoted to rheumatic diseases.
ImmuPharma recently had confirmation that the ACR Abstract
Selection Committee had accepted ImmuPharma's abstract paper on the
Company's final clinical data for its Lupuzor(TM) Phase IIb trial.
Lupuzor(TM) is ImmuPharma's potential blockbuster drug for Lupus, a
chronic autoimmune disease. Lupuzor(TM) has received Special
Protocol Assessment and Fast Track Designation from the FDA for a
Phase III trial. The title of the session is called "Systemic Lupus
Erythematosus - Clinical Aspects and Treatment".
The presentation will be given by the authors of the abstract:
ImmuPharma's President and Chief Scientific Officer, Dr. Robert
Zimmer, together with Pr. Daniel J. Wallace, Associate Director,
Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los
Angeles, and a leading practitioner within the field of Lupus, and
Prof. Sylviane Muller, Research Director at CNRS, Strasbourg,
France and the key inventor of Lupuzor(TM) . (Full biographies can
be found in 'Notes to Editors'.)
Analyst meeting: Friday 16 November at 10am
Venue: Buchanan, 107 Cheapside, London EC2V 6DN
Following the presentation at the ACR conference on 14th
November, ImmuPharma will host an analyst meeting on Friday 16
November in London to provide full disclosure of the abstract paper
and clinical analysis of the Lupuzor Phase IIb study. The
presentation will be given by Dr Robert Zimmer and ImmuPharma's
CEO, Dimitri Dimitriou. Please contact Lisa Baderoon, Head of
Investor Relations, if you would like to attend
(lisa.baderoon@immupharma.com).
Ends
For further information please contact:
ImmuPharma plc + 44 (0) 20 7152 4080
Dimitri Dimitriou, Chief Executive
Officer
Dr Robert Zimmer, President and Chief
Scientific Officer
Richard Warr, Chairman
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
Buchanan + 44 (0) 20 7466 5000
Mark Court
Panmure, Gordon & Co., NOMAD & Broker +44 (0) 20 7459 3600
Andrew Burnett
Fred Walsh
Espirito Santo Investment Bank, Joint
Broker +44 (0) 20 7456 9191
Richard Crawley
Cenkos Securities plc, Joint Broker +44 (0) 20 7397 8900
Stephen Keys, Camilla Hume
Andy Roberts
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high
sales potential in specialist markets with serious unmet need.
ImmuPharma has five drug candidates in development, two platform
technologies and approximately 70 patents. The Company's most
advanced drug candidate, Lupuzor(TM) a potential blockbuster drug
for Lupus, a chronic autoimmune disease has recently received the
approval from the US FDA to enter phase III with a Special Protocol
Assessment and "Fast Track" designation. ImmuPharma was founded and
is led by a commercially focused Board and management team with
extensive experience. www.immupharma.com
Biographies
Dr Robert Zimmer, President and Chief Science Officer,
ImmuPharma
Dr. Robert Zimmer was the founder and chief executive officer of
both ImmuPharma Switzerland and ImmuPharma France. He is an expert
in clinical pharmacology and life cycle management. He was
instrumental in developing a substantial number of products for
clients including Roche, GlaxoSmithKline, Abbott, Searle,
Sanofi-Aventis and Lilly. He began his career in Roche's
headquarters in Basle as coordinator of clinical pharmacology and
international clinical leader. He subsequently joined Jago Pharma,
the drug delivery company, and became a director and head of
research and development at SkyePharma after it acquired JAGO. He
obtained his MD at Strasbourg Medical School and his PHD at the
University of Aix-Marseille.
Dr Sylviane Muller, Research Director at CNRS & Co-founder
of ImmuPharma France
Sylviane Muller is Professor at the Institute for Advanced Study
of the University of Strasbourg (USIAS), holder of the chair of
immunology and therapeutic chemistry, Distinguished class Research
Director and head of the 'Immunologie et chimie thérapeutiques'
unit of the "Centre National de la Recherche Scientifique" (CNRS),
the largest fundamental research organization in Europe. She
obtained her PhD at the University of Strasbourg. For two years,
she was a post-doctoral fellow in Freiburg (Germany) at the
Max-Planck Institute for Immunobiology. Her field of expertise
covers autoimmunity, immuno-peptides and synthetic vaccines. She
has made 23 patented discoveries and is widely published (330
publications and reviews/chapters). She was also a founder of
Neosystem, now Polypeptide-France, a leading peptide development
and manufacturing company. She is the key inventor of ImmuPharma's
Lupus lead drug candidate Lupuzor and has been working in this
field for more than ten years.
Dr Daniel J Wallace, Associate Director, Rheumatology Fellowship
Program, Cedars-Sinai Medical Center, Los Angeles
Dr Wallace received his undergraduate and medical education at
the University of Southern California, graduating with an MD in
1974. His graduate medical training included an internship at Brown
University in Providence, Rhode Island, medical residency at
Cedars-Sinai Medical Center in Los Angeles and a fellowship in
rheumatology at UCLA. He is Board Certified in both Internal
Medicine and Rheumatology.
While a fellow at UCLA, he conducted pioneering arthritis
research that landed his picture in Time magazine and developed a
close relationship with his mentor, Edmund Dubois. Dr Dubois had
the largest lupus practice in the United States at the time and was
the principal editor of the only lupus textbook. He is the author
of 6 medical textbooks (including the last 4 editions of Dubois'
Lupus Erythematosus, All About Fibromyalgia, The Lupus Book, All
About Osteoarthritis, The New Sjogren's Syndrome Handbook, and
Fibromyalgia & Other Central Pain Syndromes), 19 book chapters,
and over 250 medical publications. The latter have appeared in the
New England Journal of Medicine, Annals of Internal Medicine, the
Lancet, Journal of Clinical Investigation, Journal of Immunology,
and Journal of the American Medical Association. Wallace's academic
efforts include having served as Chief of Rheumatology at
Cedars-Sinai Medical Center, Century City Hospital, and the City of
Hope Medical Center in Duarte, CA. He is currently a Clinical
Professor of Medicine at the David Geffen School of Medicine at
UCLA. His clinical practice is based at Cedars-Sinai, where he is
involved in the care of 2,000 lupus patients, the largest practice
of its kind in the United States. The Wallace Rheumatic Disease
Research Center currently runs over 30 clinical trials for patients
with rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic
arthritis and fibromyalgia. The center has been the recipient of 3
National Institute of Health grants. 20% of his time is spent in
teaching and research, providing free medical care.
About The American College of Rheumatology "ACR"
The American College of Rheumatology's mission is advancing
rheumatology. The organization is for physicians, health
professionals, and scientists that meets the mission through
programs of education, research, advocacy and practice support.
The ACR provides professional education for its members through
several venues. The Annual Scientific Meeting is the premier
scientific meeting devoted to the rheumatic diseases. This meeting
draws thousands of rheumatologists and arthritis health
professionals from around the world. A winter rheumatology
symposium, spring clinical meetings, and other topical conferences
round out the ACR's educational offerings.
The ACR publishes Arthritis & Rheumatism, the premier
scientific journal for research in the rheumatic diseases.
Arthritis Care & Research is published by the Association of
Rheumatology Health Professionals, a division of the ACR. This
journal focuses on the health services and clinical aspects of
rheumatology.
The Association of Rheumatology Health Professionals, a division
of the American College of Rheumatology, is a professional
membership society composed of non-physician health care
professionals specializing in rheumatology, such as advanced
practice nurses, nurses, occupational therapists, physical
therapists, psychologists, social workers, epidemiologists,
physician assistants, educators, clinicians, researchers, research
coordinators and office staff.
The ACR Annual Meeting - The Premier Meeting in Rheumatology
The ACR Annual Meeting is the must-attend event for anyone
involved in research or delivery of rheumatologic care or services.
Innovative sessions, ground breaking scientific abstracts,
education developed based on practice gaps, the return of popular
session formats, as well as hands-on skill training sessions are
just some of the highlights.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFSDLRLFIIF
Immupharma (LSE:IMM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Sep 2023 to Sep 2024